| 2025 | 2024 | 2023 | 2022 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | -5,8 k € | -70.8% | -3,4 k € | -243.9% | 2,3 k € | +171.0% | -3,3 k € | -187.7% | 3,8 k € | -61.2% | 9,7 k € | -60.5% | 24,6 k € | -47.5% | 46,9 k € | +592.6% | -9,5 k € | -113.8% | 69,0 k € | -52.7% | 145,9 k € | +77.0% | 82,4 k € | -50.9% | 167,8 k € | +74.6% | 96,1 k € | +171.0% | 35,5 k € | +568.9% | -7,6 k € | |
| EBITDA | -26,0 k € | -518.1% | -4,2 k € | -372.2% | 1,5 k € | +135.0% | -4,4 k € | -250.3% | 2,9 k € | -66.0% | 8,6 k € | -51.3% | 17,7 k € | -58.6% | 42,8 k € | +477.0% | -11,4 k € | -125.9% | 43,9 k € | +1.5% | 43,2 k € | +364.1% | -16,4 k € | -119.9% | 82,1 k € | +260.6% | 22,8 k € | +3016.7% | 730,0 € | +103.5% | -20,9 k € | |
| Operating profit | -26,0 k € | -518.1% | -4,2 k € | -372.2% | 1,5 k € | +135.0% | -4,4 k € | +10.5% | -4,9 k € | -23.9% | -4,0 k € | -874.2% | 515,0 € | -98.5% | 33,7 k € | +233.8% | -25,2 k € | -224.7% | 20,2 k € | -9.2% | 22,3 k € | +157.2% | -38,9 k € | -169.3% | 56,1 k € | +2037.9% | 2,6 k € | +137.6% | -7,0 k € | +74.2% | -27,1 k € | |
| Profit/loss | -26,3 k € | -471.4% | -4,6 k € | -434.6% | 1,4 k € | +130.4% | -4,5 k € | +35.1% | -7,0 k € | -25.1% | -5,6 k € | -113.5% | -2,6 k € | -109.5% | 27,7 k € | +216.3% | -23,8 k € | -193.8% | 25,4 k € | +21.5% | 20,9 k € | +147.4% | -44,1 k € | -181.7% | 53,9 k € | +7242.8% | 734,0 € | +110.9% | -6,8 k € | +73.8% | -25,8 k € | |
| Equity | 88,9 k € | -22.9% | 115,2 k € | -3.8% | 119,9 k € | +1.2% | 118,5 k € | -14.1% | 138,0 k € | -4.8% | 145,0 k € | -3.7% | 150,5 k € | -1.7% | 153,2 k € | +22.1% | 125,5 k € | -15.9% | 149,3 k € | +20.5% | 123,9 k € | +20.3% | 103,1 k € | -29.9% | 147,1 k € | +57.8% | 93,2 k € | +0.8% | 92,5 k € | -6.8% | 99,2 k € | |
| Total assets | 290,0 k € | -7.3% | 313,0 k € | -5.6% | 331,5 k € | -7.8% | 359,4 k € | -23.0% | 466,6 k € | -10.5% | 521,6 k € | -10.7% | 584,1 k € | +1.8% | 573,6 k € | +14.2% | 502,4 k € | -6.2% | 535,4 k € | +14.1% | 469,1 k € | +24.4% | 377,0 k € | +5.8% | 356,3 k € | +18.7% | 300,2 k € | +189.4% | 103,7 k € | -15.6% | 122,8 k € | |
| Cash | 2,8 k € | +20.9% | 2,3 k € | -89.0% | 20,7 k € | -59.6% | 51,3 k € | +233.9% | 15,4 k € | -31.9% | 22,5 k € | -46.9% | 42,5 k € | -25.0% | 56,7 k € | -0.0% | 56,7 k € | -24.1% | 74,7 k € | +16.2% | 64,3 k € | +64.6% | 39,0 k € | -57.8% | 92,4 k € | +14.6% | 80,7 k € | +263.8% | 22,2 k € | -63.6% | 60,9 k € | |
| Debts | 201,1 k € | +1.7% | 197,8 k € | -6.6% | 211,7 k € | -12.1% | 240,9 k € | -26.6% | 328,2 k € | -11.5% | 371,0 k € | -13.9% | 431,0 k € | +3.0% | 418,5 k € | +15.7% | 361,7 k € | -5.2% | 381,5 k € | +12.7% | 338,5 k € | +29.3% | 261,8 k € | +26.8% | 206,4 k € | +5.9% | 194,9 k € | +1732.4% | 10,6 k € | -52.1% | 22,2 k € | |
| Staff | — | — | — | — | — | — | — | — | — | 0,5 | 2,2 | 2,2 | 2,4 | 1,5 | 1,2 | 0,4 | ||||||||||||||||
Public limited company · Knokke-Heist · incorporated on 29/08/2006
Public limited company loss-making in the latest fiscal year. Cash position rising (+20.9%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
PHARMACOSMEDICS is a Public limited company incorporated in 2006. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Knokke-Heist.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette